Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study-Reference-Cited by-同舟云学术

Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study

Published:2021-01-23 Issue:2 Volume:41 Page:169-176
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Casale Matteo,Correale Michele^ORCID,Laterra Giulia,Vaccaro Vittoria,Morabito Claudia,Crea Pasquale,Signorelli Salvatore Santo,Katsiki Niki,Luzza Francesco,de Gregorio Cesare,Dattilo Giuseppe

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40261-020-00995-3.pdf

Reference35 articles.

1. Blood AJ, Fraiche AM, Eapen ZJ. Is an admission for decompensated heart failure inevitable? Prog Cardiovasc Dis. 2017;60:171–7.

2. Camplain R, Kucharska-Newton A, Keyserling TC, Layton JB, Loehr L, Heiss G. incidence of heart failure observed in emergency departments, ambulatory clinics, and hospitals. Am J Cardiol. 2018;11:1328–35.

3. Khan SS, Ning H, Shah SJ, Yancy CW, Carnethon M, Berry JD, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73:2388–97.

4. Ziaeiana B, Fonarowc GC. The prevention of hospital readmissions in heart failure. Prog Cardiovasc Dis. 2016;58:379–85.

5. Zacà V. Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis. J Cardiovasc Med (Hagerstown). 2018;19(10):597–605.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?;Heart Failure Reviews;2024-07-23

2. Angiotensin Receptor/Neprilysin Inhibitor in Patients with an Implantable Cardioverter-Defibrillator: Systematic Review and Meta-Analysis;2024

3. Ventricular tachycardia and non-Hodgkin's lymphoma. Syncope in a 33-year-old young;Cor et Vasa;2023-10-15

4. The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population;Journal of Clinical Medicine;2023-09-28

5. Atrial fibrillation and QT corrected. What is the best formula to use?;European Journal of Clinical Investigation;2023-05-12